We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
- Authors
Budman, Daniel R.; Johnson, Robert; Barile, Barbara; Bowsher, Ronald R.; Vinciguerra, Vincent; Allen, Steven L.; Kolitz, Jonathan; Ernest, Steven C.; Kreis, Willi; Zervos, Peter; Walling, Jackie; Budman, D R; Johnson, R; Barile, B; Bowsher, R R; Vinciguerra, V; Allen, S L; Kolitz, J; Ernest, C S 2nd; Kreis, W
- Abstract
<bold>Purpose: </bold>In this phase I trial in humans the safety and pharmacology of LY309887 on a weekly schedule combined with daily oral 5-mg doses of folic acid were evaluated.<bold>Background: </bold>LY309887 is an inhibitor of folate-dependent enzymes involved in de novo purine biosynthesis and has a broad preclinical antitumor activity. In murine systems, combining this agent with exogenous folic acid results in an enhanced therapeutic index.<bold>Methods: </bold>This study was a single-institution, open-label, clinical trial of dose escalation with toxicity and pharmacokinetic parameters determined. The dose range studied was 0.5-4 mg/m2 per week x6 and then a modified schedule weekly x3 every 6 weeks.<bold>Results: </bold>Dose-limiting toxicities were of delayed onset and associated with hematologic, neurologic, and mucosal effects. Pharmacokinetic parameters revealed dose linearity for AUC and Cmax. Low circulating levels of drug persisted for over 200 h. Urinary excretion accounted for approximately 50% of the parent drug but was highly variable. The urinary excretion was near maximal within 24 h of dosing.<bold>Conclusions: </bold>The modified dosing schedule allowed repetitive dosing in patients. Further evaluation of the 2 mg/m2 per week x3 every 6 weeks with daily oral folate supplement as a potential phase II dose may be warranted.
- Subjects
CLINICAL trials; PHARMACOKINETICS; PHARMACOLOGY; ORAL drug administration; ANTINEOPLASTIC agents; DRUGS; PATIENTS
- Publication
Cancer Chemotherapy & Pharmacology, 2001, Vol 47, Issue 6, p525
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s002800000272